CardioSource WorldNews | Page 7

LIVE
COURSES

2016

May 5–7

Recent Advances in Clinical
Nuclear Cardiology and
Cardiac CT: State of the Art
Updates & 101 EvidenceBased Case Reviews

October 20–22

Heart Valve Summit: Medical,
Surgical & Interventional
Decision-Making Course
Radisson Blu Aqua Hotel
Chicago, IL

October 8

October 15

Lexington Convention Center
Lexington , KY

Columbus Hotel at Easton
Columbus, OH

Kentucky Chapter Annual
Meeting 2016
B:7.875 in

Ohio Chapter Annual Meeting
2016

T:7.5 in

Capital Hilton
Washington, DC

S:7 in

June 4–7

Add Corlanor ® to maximally tolerated doses of beta-blockers and help give

World Heart Federation |
World Congress of Cardiology
& Cardiovascular Health 2016

appropriate patients with heart rate ≥ 70 bpm and stable, symptomatic chronic HF...

MORE HOME. LESS HOSPITAL.

Mexico City, Mexico

June 3–4

Bringing Science to Clinical
Practice: Best of ACC.16
1 Hotel South Beach
Miami, FL

June 17–18

Care of the Athletic Heart:
Translating Clinical Science
into Practice Strategies
The Westin Houston-Memorial City
Houston, TX

August 19–21

Florida Chapter Annual
Meeting 2016
Disney’s Yacht Club Resort
Orlando, FL

August 26–28

Learn how you can DO MORE with Corlanor® to reduce the risk
of hospitalization for worsening heart failure (HF)

ACC/SCAI Premier
Interventional Cardiology
Overview & Board
Preparatory Course
The Ritz-Carlton
Amelia Island, FL

September 6–10

The ACC Cardiovascular Board
Review for Certification &
Recertification
The Swissotel
Chicago, IL

September 14– 17

Core Curriculum for the
Cardiovascular Clinician
Heart House
Washington, DC

September 23–25

NC/SC Chapters Annual
Meeting 2016
Kiawah Island Golf Resort
Kiawah Island, SC

1

CorlanorHCP.com
Indication
Corlanor® (ivabradine) is indicated to reduce the risk of hospitalization
for worsening heart failure in patients with stable, symptomatic
chronic heart failure with left ventricular ejection fraction ≤ 35%, who
are in sinus rhythm with resting heart rate ≥ 70 beats per minute and
either are on maximally tolerated doses of beta-blockers or have a
contraindication to beta-blocker use.

Important Safety Information
Contraindications: Corlanor® is contraindicated in patients with
acute decompensated heart failure, blood pressure < 90/50 mmHg,
sick sinus syndrome, sinoatrial block, 3rd degree atrioventricular
block (unless a functioning demand pacemaker is present), a resting
heart rate < 60 bpm prior to treatment, severe hepatic impairment,
pacemaker dependence (heart rate maintained exclusively by the
pacemaker), and concomitant use of strong cytochrome P450 3A4
(CYP3A4) inhibitors.
Fetal Toxicity: Corlanor® may cause fetal toxicity when administered
to a pregnant woman based on embryo-fetal toxicity and cardiac
teratogenic effects observed in animal studies. Advise females to use
effective contraception when taking Corlanor®.
Atrial Fibrillation: Corlanor® increases the risk of atrial fibrillation.
The rate of atrial fibrillation in patients treated with Corlanor®
compared to placebo was 5% vs. 3.9% per patient-year, respectively.
Regularly monitor cardiac rhythm. Discontinue Corlanor® if atrial
fibrillation develops.

© 2015 Amgen Inc. All rights reserved. Not for reproduction. USA-998-115485 11-15

Bradycardia and Conduction Disturbances: Bradycardia, sinus
arrest and heart block h fR